Brief: Biosenic Updates On Current License Agreement With Phebra
May 29 (Reuters) - Bone Therapeutics SA BIOS.BR :
* BIOSENIC PROVIDES UPDATE REGARDING CURRENT LICENSE
AGREEMENT
WITH PHEBRA
* MAINTENANCE OF LICENSE IS NOW SUBJECT TO LAUNCH OF OATO
PHASE
III BEFORE MAY 2024 INSTEAD OF 31 MAY 2023
* PARTIES ALSO CURRENTLY NEGOTIATING A POTENTIAL
RENEGOTIATION OF
OTHER LICENSING TERMS
Source text for Eikon: ID:nGNE2kdYtG
Further company coverage: BIOS.BR
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Biosenic SA
See all newsBrief: Biosenic Says Enterprise Court Of Nivelles Approves Co's Restructuring Plan
Brief: Biosenic Anticipates Having Sufficient Cash To Carry Out Its Business Objectives Until Q3 2024
Brief: BioSenic Patent Granted In Canada For Broader Protection Of ATO Therapeutic Platform
Brief: Biosenic Files For Additional Patent Protection For Osteoarthritis Drug
Brief: BioSenic Signs New Binding Term Sheet With Phebra PTY Ltd